Zevra Therapeutics, Inc. Investigation - ZVRA

Company: Zevra Therapeutics, Inc. (NASDAQ: ZVRA)

Learn more about the Zevra Therapeutics, Inc. Investigation

Required Field

$1 - $1,000
$1001 - $10,000
$10,001 - $25,000
$25,001 - $50,000
$50,001 - $100,000
$100,001 - $250,000
$250,001 - $500,000
$500,000+

Full Name

There is no cost or obligation for you to submit.

The submission of this form does not create an attorney-client relationship.

* By checking this box, you agree to receive text messages from us, at the cell number you provided above, regarding new cases and case updates. Reply STOP to cancel. Msg frequency varies. Msg and data rates may apply. View Terms & Privacy

Please Upload related files below

Add Transactions

Purchases

1.

Common Stock
Preferred Stock
Bonds
Calls
Puts

Additional Purchases

Sales

1.

Common Stock
Preferred Stock
Bonds
Calls
Puts

Additional Sales

Please input at least 1 transaction or press "skip for now" button below

Please fill in all the fields for your transaction or press "skip for now" button below

Upload Your Stock Tickers

Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.

Don’t miss out on possible monetary recovery - link your brokerage account with SnapTrade.

Zevra Therapeutics, Inc. Investigation Details

July 24, 2026 brought a roughly 24% pre-market drop in Zevra Therapeutics after the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) issued a negative opinion on the Marketing Authorization Application for arimoclomol, branded Meplyffa, for Niemann-Pick disease type C. The CHMP opinion was announced before regular trading and triggered an immediate selloff in Zevra shares. Financial news reports described the decline as the stock’s worst single-day percentage loss in more than five years. The regulatory decision concerned arimoclomol, Zevra’s lead product for Niemann-Pick disease type C. Following the CHMP’s negative opinion, Zevra announced that it intends to request a re-examination of the decision and would continue providing arimoclomol to eligible patients through its global Expanded Access Program pending further regulatory review.

Get Started